WO2021247397A3 - Methods and compositions for enhancing the immune system - Google Patents

Methods and compositions for enhancing the immune system Download PDF

Info

Publication number
WO2021247397A3
WO2021247397A3 PCT/US2021/034777 US2021034777W WO2021247397A3 WO 2021247397 A3 WO2021247397 A3 WO 2021247397A3 US 2021034777 W US2021034777 W US 2021034777W WO 2021247397 A3 WO2021247397 A3 WO 2021247397A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
enhancing
subject
immune system
immunosenescence
Prior art date
Application number
PCT/US2021/034777
Other languages
French (fr)
Other versions
WO2021247397A2 (en
Inventor
Lewis S. Gruber
Original Assignee
Siwa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siwa Corporation filed Critical Siwa Corporation
Publication of WO2021247397A2 publication Critical patent/WO2021247397A2/en
Publication of WO2021247397A3 publication Critical patent/WO2021247397A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

A method of enhancing the immune system, treating immunosenescence or preventing immunosenescence comprises administering to a subject a composition comprising an anti-AGE antibody. A method of enhancing the immune system, treating immunosenescence or preventing immunosenescence comprises administering to a subject a vaccine comprising an AGE antigen. A method of killing senescent immune cells in a subject comprises administering to the subject a composition comprising an anti-AGE antibody. The senescent immune cells are selected from the group consisting of white blood cells, mast cells, natural killer cells (NK cells), eosinophils, basophils, gamma/delta T cells (γδ T cells), phagocytic cells, macrophages, neutrophils, dendritic cells, T cells and B cells.
PCT/US2021/034777 2020-06-04 2021-05-28 Methods and compositions for enhancing the immune system WO2021247397A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063034920P 2020-06-04 2020-06-04
US63/034,920 2020-06-04

Publications (2)

Publication Number Publication Date
WO2021247397A2 WO2021247397A2 (en) 2021-12-09
WO2021247397A3 true WO2021247397A3 (en) 2022-01-13

Family

ID=78831703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/034777 WO2021247397A2 (en) 2020-06-04 2021-05-28 Methods and compositions for enhancing the immune system

Country Status (1)

Country Link
WO (1) WO2021247397A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616728T3 (en) 2008-05-23 2017-06-14 Siwa Corporation Procedures and compositions to facilitate regeneration
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
CA3021150C (en) 2016-02-19 2023-02-07 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
KR20180133452A (en) 2016-04-15 2018-12-14 시와 코퍼레이션 Anti-aging antibodies to treat neurodegenerative diseases
EP3609923A1 (en) 2017-04-13 2020-02-19 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN115074430A (en) * 2022-06-16 2022-09-20 广州惠善医疗技术有限公司 Immune aging detection system for immune-related disease patients and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160083437A1 (en) * 2012-11-30 2016-03-24 Industry Foundation Of Chonnam National University Composition comprising recombinant fusion protein of pathogenic antigen protein and flagellin of vibrio vulnificus for preventing, alleviating, or treating aging
US20160215043A1 (en) * 2014-12-18 2016-07-28 Siwa Corporation Product and method for treating sarcopenia
US20160311907A1 (en) * 2013-12-20 2016-10-27 Jennifer Brogdon Regulatable chimeric antigen receptor
US20190328873A1 (en) * 2016-06-23 2019-10-31 Siwa Corporation Vaccines for use in treating various diseases and disorders
US20200054682A1 (en) * 2018-08-14 2020-02-20 Imel Biotherapeutics, Inc. Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
WO2020041625A1 (en) * 2018-08-23 2020-02-27 Siwa Corporation Anti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160083437A1 (en) * 2012-11-30 2016-03-24 Industry Foundation Of Chonnam National University Composition comprising recombinant fusion protein of pathogenic antigen protein and flagellin of vibrio vulnificus for preventing, alleviating, or treating aging
US20160311907A1 (en) * 2013-12-20 2016-10-27 Jennifer Brogdon Regulatable chimeric antigen receptor
US20160215043A1 (en) * 2014-12-18 2016-07-28 Siwa Corporation Product and method for treating sarcopenia
US20190328873A1 (en) * 2016-06-23 2019-10-31 Siwa Corporation Vaccines for use in treating various diseases and disorders
US20200054682A1 (en) * 2018-08-14 2020-02-20 Imel Biotherapeutics, Inc. Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
WO2020041625A1 (en) * 2018-08-23 2020-02-27 Siwa Corporation Anti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUNG ET AL.: "Advanced glycation end products induce T cell apoptosis: Involvement of oxidative stress, caspase and the mitochondrial pathway", MECHANISMS OF AGEING AND DEVELOPMENT, vol. 131, 1 October 2010 (2010-10-01), pages 682 - 691, XP027552606 *

Also Published As

Publication number Publication date
WO2021247397A2 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
WO2021247397A3 (en) Methods and compositions for enhancing the immune system
Vargas-Inchaustegui et al. Distinct roles for MyD88 and Toll-like receptor 2 during Leishmania braziliensis infection in mice
Hurez et al. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice
Aliberti et al. Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes
Kastenmüller et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets
Gershoff et al. Some effects of amino acid deficiencies on antibody formation in the rat
DE60234115D1 (en) PHARMACEUTICAL COMPOSITION FOR INDUCING AN IMMUNE RESPONSE TO A HUMAN OR ANIMAL
WO2006002079A8 (en) Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
CN104147599A (en) Vaccine adjuvant as well as preparation method and application thereof
Cardillo et al. An age‐related γδ T cell suppressor activity correlates with the outcome of autoimmunity in experimental Trypanosoma cruzi infection
Kedar et al. Enzymatic enhancement of cell-mediated cytotoxicity and antibody-dependent cell cytotoxicity
Wirth et al. Secondary CD8+ T‐cell responses are controlled by systemic inflammation
Norval et al. UV-induced immunosuppression and the efficacy of vaccination
Bittner-Eddy et al. Mucosal Langerhans cells promote differentiation of Th17 cells in a murine model of periodontitis but are not required for Porphyromonas gingivalis–driven alveolar bone destruction
Pang et al. Cooperation between mouse T-cell subpopulations in the cell-mediated response to a natural poxvirus pathogen
Wu et al. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides
Apte et al. Subcutaneous cholera toxin exposure induces potent CD 103+ dermal dendritic cell activation and migration
Bijker et al. Studying the effect of chloroquine on sporozoite-induced protection and immune responses in Plasmodium berghei malaria
Li et al. Protective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice
AU5441299A (en) Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
Berzofsky A push–pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses
PT1238086E (en) VACCINE TO INCREASE IMMUNE RESPONSES TO THE VACCINE AGAINST SIMPLE HERPES VIRUSES
Lee et al. Dimorphic Plasmodium falciparum merozoite surface protein‐1 epitopes turn off memory T cells and interfere with T cell priming
DE3818054C2 (en) Use of a combination of an antigen or a vaccine and human interleukin for the treatment of non-responsiveness to immunological defect states
Youssef et al. Effector mechanisms in murine allograft rejection: comparison of skin and heart grafts in fully allogeneic and minor histocompatibility antigen‐mismatched strain combinations

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21818548

Country of ref document: EP

Kind code of ref document: A2